ARTICLE | Company News
AstraZeneca, Isis expand antisense collaboration
August 4, 2015 12:53 AM UTC
AstraZeneca plc (LSE:AZN; NYSE:AZN) and Isis Pharmaceuticals Inc. (NASDAQ:ISIS) partnered to discover and develop antisense therapeutics against undisclosed targets for cardiovascular, metabolic and renal diseases.
Isis spokesperson Amy Blackley said Isis will be responsible for discovery, and AstraZeneca will lead development once candidates are selected. ...